Alterity to Present at Hidden Gems in Life Sciences Webinar
Released
Released
Announcement PDF
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life
Sciences’ Webinar
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 13 June 2024: Alterity Therapeutics
(ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated
to developing disease modifying treatments for neurodegenerative diseases, today announced
that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST
Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia /
Wednesday, 12 June 2024 in the United States.
Details are listed below and registration is required.
Webcast details
AUSTRALIA PARTICIPANTS:
Date: Thursday, 13 June 2024
Time: 1:30 p.m. AEST (Sydney/Melbourne)
UNITED STATES PARTICIPANTS:
Date: Wednesday, 12 June 2024
Time: 8:30 p.m. Pacific Time
11:30 p.m. Eastern Time
To join the presentation, please click the webinar link here.
Investors will have the opportunity to ask questions during the call, at the conclusion of the
presentation.
A recording of the webinar will be made available on the Alterity Therapeutics website after the
event, which you can access here: www.alteritytherapeutics.com.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has
the potential to treat various Parkinsonian disorders and is currently being evaluated in two
Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery
platform generating patentable chemical compounds to treat the underlying pathology of
neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s website at
www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Share your feedback
Discover